Twist Bioscience
TWST
$49.17
-7.14%
Twist Bioscience is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. The current investor narrative is centered on its disruptive technology platform's potential to capture significant market share in the rapidly growing fields of biopharma, data storage, and diagnostics, with recent attention likely driven by its inclusion in high-profile thematic funds focused on innovation and its demonstrated revenue growth trajectory. Recent news highlighting ARK Invest's performance suggests continued institutional interest in disruptive tech names like Twist, reinforcing the growth story.…
TWST
Twist Bioscience
$49.17
Related headlines
Investment Opinion: Should I buy TWST Today?
Rating: Hold. The core thesis is that TWST possesses a disruptive platform with clear scaling benefits, but its extreme cash burn and recent loss of momentum warrant caution until the path to profitability becomes more visible.
The Hold rating is supported by a mix of promising and concerning data points. Positively, revenue growth is robust at 16.89% YoY, gross margins are expanding healthily to 52.05%, and the valuation (PS of 4.47x) is at a multi-year low, reducing downside risk. Analyst sentiment remains bullish. However, these are counterbalanced by deeply negative profitability metrics (net margin: -29.4%), unsustainable cash burn (FCF: -$86.7M TTM), and severe negative momentum over the past month (-14.67%).
The two biggest risks that could invalidate a neutral stance are an acceleration in cash burn requiring a dilutive capital raise, or a deceleration in revenue growth below 10% YoY. This Hold would upgrade to a Buy if the company demonstrates two consecutive quarters of sequential improvement in operating cash flow or provides clear guidance for reaching cash flow breakeven. It would downgrade to a Sell if quarterly revenue growth falls below 10% or if the cash balance declines precipitously without a clear funding plan. Relative to its own history, the stock appears fairly valued, but it remains a premium-priced, speculative growth story demanding flawless execution.
Sign up to view all
TWST 12-Month Price Forecast
TWST is a classic 'show me' story at an inflection point. The operational metrics are directionally positive, showing a company that is scaling its disruptive platform. However, the financials reveal the high cost of that growth, with profitability and cash generation remaining distant goals. The neutral stance reflects this balance: the risk/reward is not compelling enough for a Buy given the cash burn and momentum reversal, but the underlying business progress and reset valuation argue against a Sell. Confidence is medium due to the limited analyst coverage and high volatility. The stance would upgrade to bullish on concrete evidence of operating leverage reducing cash burn. It would turn bearish on any material slowdown in top-line growth or a capital raise announcement.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Twist Bioscience's 12-month outlook, with a consensus price target around $63.92 and implied upside of +30.0% versus the current price.
Average Target
$63.92
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$39 - $64
Analyst target range
Analyst coverage for TWST appears limited, with only 6 analysts providing estimates for future EPS and revenue, and no explicit consensus price target, recommendation distribution, or target range provided in the dataset. The provided institutional ratings show a pattern of reiterated bullish calls (Buy, Overweight, Outperform) from firms like Barclays, Guggenheim, and Evercore ISI throughout late 2025 and early 2026, with the latest action in March 2026. This suggests that the covering analysts maintain a positive outlook. However, the absence of quantified price targets and the low analyst count indicates this is still a stock with limited institutional coverage, which is typical for a mid-cap, pre-profitability growth company. This limited coverage can lead to higher volatility and less efficient price discovery, as the stock's narrative is driven by a smaller set of opinions and more susceptible to macro sentiment shifts and thematic investing flows, as evidenced by its inclusion in ARK Invest's disruptive innovation strategy.
Bulls vs Bears: TWST Investment Factors
The investment debate for TWST centers on the tension between its demonstrable operational progress and its persistent, costly unprofitability. The bull case, currently supported by stronger evidence, is built on tangible improvements: accelerating revenue growth, expanding gross margins, and a valuation that has reset to a more reasonable level after a historic de-rating. However, the bear case presents a formidable counter-argument anchored in the unsustainable cash burn rate of -$86.7M TTM and the recent sharp reversal in price momentum. The single most important factor that will determine the thesis is the trajectory of operating cash flow. If TWST can demonstrate a credible path to cash flow breakeven through continued margin expansion and operating leverage, the bull narrative will solidify. Conversely, if cash burn persists or accelerates, it will validate bearish concerns about capital dependency and force a re-rating lower, regardless of top-line growth.
Bullish
- Robust Revenue Growth & Scaling: Q1 2026 revenue grew 16.89% YoY to $103.7M, continuing a sequential climb from $75.3M in Q2 2024. This demonstrates the core business is scaling effectively, with both Antibody Discovery ($51.06M) and NGS Tools ($52.64M) segments contributing nearly equally, indicating diversified growth drivers.
- Significantly Improved Gross Margins: Gross margin expanded to 52.05% in Q1 2026, up from 48.29% a year prior. This 376 basis point improvement signals increasing pricing power and operational leverage from the silicon-based manufacturing platform, a critical step toward eventual profitability.
- Valuation De-rating to Sustainable Levels: The trailing PS ratio of 4.47x is near the bottom of its historical range, having compressed from over 30x in early 2025 and 180x in 2021. This massive de-rating from speculative highs to a more grounded multiple based on scaling revenue reduces valuation risk and provides a firmer foundation for future gains.
- Strong Institutional Conviction: Analysts from Barclays, Guggenheim, and Evercore ISI reiterated bullish ratings (Buy/Overweight) in early 2026. This sustained institutional support, coupled with thematic interest from funds like ARK Invest, provides a narrative tailwind despite limited quantitative coverage from only 6 analysts.
Bearish
- Persistent & Significant Cash Burn: The company is burning cash at an alarming rate, with TTM free cash flow of -$86.7M and Q1 2026 operating cash flow of -$24.8M. This unsustainable burn, despite revenue growth, necessitates future capital raises that could dilute shareholders, as profitability remains elusive with a -29.4% net margin.
- Extreme Volatility & Momentum Reversal: The stock's beta of 2.227 indicates it is more than twice as volatile as the market. Recent momentum has sharply reversed, with a -14.67% return over the past month versus the S&P 500's +5.6%, signaling a loss of investor confidence and high susceptibility to risk-off sentiment.
- Unprofitability and Negative Returns: The company reported a Q1 2026 net loss of -$30.5M, translating to a net margin of -29.4%. Asset efficiency metrics are deeply negative (ROA: -12.94%, ROE: -16.42%), reflecting the high cost of the growth-at-all-costs strategy and raising questions about the timeline to sustainable earnings.
- Limited Analyst Coverage & Price Discovery: Only 6 analysts provide estimates, and no explicit consensus price target is available. This limited coverage leads to less efficient price discovery, making the stock more vulnerable to narrative shifts and thematic flows rather than fundamental analysis, increasing investment risk.
TWST Technical Analysis
The stock is in a sustained, volatile uptrend over the past year, evidenced by a 1-year price change of +63.36%. As of the latest close of $49.17, the stock is trading at approximately 49% of its 52-week range ($23.30 to $66.06), indicating a position in the middle of its annual band after a significant rally from the lows. This positioning suggests the explosive momentum from late 2025 to early 2026 has moderated, and the stock is now consolidating its gains, with the mid-range level representing a battleground between bulls and bears. Recent momentum shows a sharp divergence from the longer-term uptrend, with the stock down -14.67% over the past month, contrasting sharply with its +82.99% gain over six months. This 1-month decline, coupled with a 3-month return of just +0.12%, signals a significant loss of short-term momentum and a potential consolidation or correction phase following the parabolic rise earlier in the year. The stock's extreme volatility is confirmed by a beta of 2.227, meaning it is more than twice as volatile as the broader market, which is critical for risk assessment. Key technical levels are the 52-week high of $66.06, which now serves as major resistance, and the 52-week low of $23.30 as major support. A breakout above $66 would signal a resumption of the primary bull trend, while a sustained break below the recent consolidation low near $45 could indicate a deeper correction toward the $40 support zone.
Beta
2.23
2.23x market volatility
Max Drawdown
-39.9%
Largest decline past year
52-Week Range
$23-$66
Price range past year
Annual Return
+63.4%
Cumulative gain past year
| Period | TWST Return | S&P 500 |
|---|---|---|
| 1m | -14.7% | +4.1% |
| 3m | +0.1% | +8.4% |
| 6m | +83.0% | +12.0% |
| 1y | +63.4% | +24.4% |
| ytd | +51.8% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TWST Fundamental Analysis
Revenue growth remains robust, with the most recent quarterly revenue (Q1 2026) at $103.7 million, representing a year-over-year growth rate of 16.89%. This continues a multi-quarter trend of sequential revenue increases from $75.3 million in Q2 2024, indicating a steady acceleration in the top line. Segment data shows a balanced contribution, with Antibody Discovery at $51.06 million and NGS Tools at $52.64 million for the latest period, suggesting both core business lines are driving growth in tandem. The company remains unprofitable on a net income basis, reporting a Q1 2026 net loss of -$30.5 million, which equates to a net margin of -29.4%. However, gross margins are healthy and improving, with the latest quarterly gross margin at 52.05%, up from 48.29% a year prior, indicating scaling benefits and pricing power. The operating margin of -31.73% shows that while gross profit is growing, operating expenses (particularly R&D and SG&A) remain high as the company invests heavily for future growth, a common characteristic of a pre-profitability growth story. The balance sheet shows a strong liquidity position with a current ratio of 3.64 and a manageable debt-to-equity ratio of 0.29. However, cash flow generation is a concern; trailing twelve-month free cash flow is deeply negative at -$86.7 million, and operating cash flow for the latest quarter was -$24.8 million. The company's ROE of -16.42% and ROA of -12.94% reflect the current unprofitability and inefficient use of assets, which is expected for a company in this investment-heavy growth phase but underscores the reliance on external capital to fund operations and expansion.
Quarterly Revenue
$103698000.0B
2025-12
Revenue YoY Growth
+0.16%
YoY Comparison
Gross Margin
+0.52%
Latest Quarter
Free Cash Flow
$-86724000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TWST Overvalued?
Given the company's negative net income, we lead with the Price-to-Sales (PS) ratio for valuation. The trailing PS ratio is 4.47x, while the Enterprise Value-to-Sales (EV/Sales) is higher at 7.90x, reflecting the company's net debt/cash position. There is no forward PS data provided, but the significant gap between the market cap-based PS and the higher EV/S suggests the market is valuing the enterprise, including its growth potential, at a premium to its current revenue base. Compared to industry averages, data is not available in the provided dataset for a direct sector PS comparison. However, a PS ratio of 4.47x for a company growing revenue at nearly 17% YoY with 50%+ gross margins could be considered reasonable or even discounted within the high-growth life tools and diagnostics sector, where peers often trade at much higher sales multiples, though this requires external benchmark data for confirmation. Historically, the stock's own PS ratio has compressed dramatically from extreme levels; the current PS of 4.47x is near the bottom of its observable historical range from the provided data, which shows PS ratios above 30x as recently as early 2025 and over 180x in 2021. This massive de-rating reflects the market's shift from valuing pure speculative growth to a more grounded assessment based on scaling revenues and a path to profitability, placing the current valuation at a more sustainable level if execution continues.
PE
-21.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -41x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-31.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are dominated by the company's profound cash consumption. With TTM free cash flow at -$86.7M and quarterly operating cash flow at -$24.8M, TWST is funding growth entirely through its balance sheet. While the current ratio of 3.64 provides a buffer, the -29.4% net margin and -31.73% operating margin indicate profitability is distant. The company's growth is contingent on continued heavy investment in R&D and SG&A, creating a binary outcome: either these investments yield scalable returns, or they represent a prolonged drain on capital that will necessitate dilutive equity raises or debt accumulation.
Market & Competitive Risks are heightened by the stock's extreme volatility (beta: 2.227) and its current valuation context. Trading at a PS of 4.47x and an EV/Sales of 7.90x, the market is pricing in significant future growth. Any disappointment in revenue acceleration or margin expansion could trigger a severe multiple compression, especially given the stock's history of trading at far higher multiples. As a thematic play on synthetic biology, its price is also vulnerable to sector rotation out of high-growth, pre-profitability names, particularly in a rising interest rate environment. The limited analyst coverage (6 analysts) exacerbates this, leading to less stable price discovery.
Worst-Case Scenario involves a 'growth stall' combined with a risk-off market environment. In this scenario, quarterly revenue growth decelerates below 10% YoY, gross margins plateau, and cash burn fails to improve. This would trigger analyst downgrades, a loss of thematic investor interest (e.g., ARK funds), and a flight to safety. The stock could re-test its 52-week low of $23.30, representing a downside of approximately -53% from the current price of $49.17. A more realistic severe bear case might see the stock fall to the $35-$40 range, a -20% to -29% decline, as it prices in a longer path to profitability and increased cost of capital.
FAQ
The key risks are, in order of severity: 1) Financial Sustainability Risk: The company's massive cash burn (-$86.7M TTM) necessitates future funding, risking shareholder dilution if equity is raised. 2) Execution & Growth Risk: Revenue growth must remain robust (currently 16.89% YoY) to justify the valuation; any slowdown could trigger a sharp multiple contraction. 3) Market Sentiment Risk: With a beta of 2.227, the stock is highly volatile and vulnerable to sector rotations out of unprofitable growth stocks, especially in a rising rate environment. 4) Competitive & Technological Risk: As a synthetic biology disruptor, it faces competition from both established players and new entrants, and its technology must maintain its edge.
Our 12-month forecast outlines three scenarios. The Base Case (50% probability) sees the stock trading between $48 and $60, as it consolidates recent gains with steady growth but persistent cash burn. The Bull Case (30% probability) targets $66 to $75, driven by accelerating growth, margin expansion, and improved cash flow visibility. The Bear Case (20% probability) warns of a drop to $30-$40 if growth disappoints and cash burn forces a dilutive capital raise. The Base Case is most likely, predicated on the assumption that the company maintains its current operational trajectory without a major positive or negative catalyst altering the investment narrative.
TWST appears fairly valued relative to its own tumultuous history but carries a premium based on future growth expectations. Its trailing Price-to-Sales (PS) ratio of 4.47x is near the bottom of its multi-year range, having compressed from over 30x, suggesting much of the speculative excess has been wrung out. However, the higher Enterprise Value-to-Sales (EV/S) of 7.90x indicates the market is still valuing the enterprise, including its growth potential, at a significant premium to current sales. The valuation implies the market expects sustained high-teens revenue growth and successful margin expansion to eventually justify the price. It is not clearly undervalued without a near-term catalyst for profitability.
TWST is a speculative buy only for investors with a high risk tolerance and a long-term investment horizon. The stock offers significant potential upside if its disruptive DNA synthesis platform continues to scale and eventually achieves profitability, supported by 16.89% revenue growth and expanding 52.05% gross margins. However, it carries substantial downside risk due to its extreme cash burn (-$86.7M TTM), lack of profits, and high volatility (beta 2.227). For most investors, it is prudent to adopt a 'Hold and monitor' approach, waiting for clearer evidence of improving cash flow before committing new capital.
TWST is unequivocally a long-term investment, unsuitable for short-term trading due to its extreme volatility and lack of near-term earnings catalysts. The company is in a capital-intensive growth phase, and the investment thesis hinges on its multi-year potential to dominate the synthetic biology market and achieve profitability. The high beta of 2.227 makes it a poor vehicle for short-term bets, as it can swing wildly on market sentiment. Given the need to navigate potential future capital raises and the long runway to earnings, investors should have a minimum holding period of 3-5 years to allow the business story to unfold. It pays no dividend and offers no income, purely relying on capital appreciation from execution success.